Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01698281 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Trial of AEZS-108 in Chemotherapy Refractory in Triple Negative Breast Cancer
A Phase 2 study, sponsored by AEterna Zentaris.
- Terminated
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
NCT01698281 is a Phase 2 study that was terminated before completion, run by AEterna Zentaris. The registered enrollment target is 7 participants.
The verdict
NCT01698281, a Phase 2 study, was terminated before completion, sponsored by AEterna Zentaris.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
Study Summary
This is a therapeutic exploratory Phase 2 study evaluating AEZS-108 compared to standard single agent cytotoxic chemotherapy (SSCC) as measured by the median time of progression-free survival (PFS) in patients with chemotherapy refractory triple negative (ER/PR/HER2-negative) LHRH-R positive metastatic breast cancer.
Interventions
- DRUG Dexamethasone
- DRUG AEZS-108
- DRUG SCCC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2012-12 |
| Est. Completion | 2014-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01698281
The ClinicalTrials.gov registry entry for NCT01698281 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AEterna Zentaris, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Dexamethasone is the first listed.
NCT01698281 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01698281 about?
NCT01698281 is a clinical study titled "Phase 2 Trial of AEZS-108 in Chemotherapy Refractory in Triple Negative Breast Cancer". This is a therapeutic exploratory Phase 2 study evaluating AEZS-108 compared to standard single agent cytotoxic chemotherapy (SSCC) as measured by the median time of progression-free survival (PFS) in patients with chemotherapy refractory triple negative (ER/PR/HER2-negative) LHRH-R positive metasta...
What is the current status of trial NCT01698281?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2012-12. Estimated completion is 2014-10.
What interventions are being tested in trial NCT01698281?
The interventions under investigation include: Dexamethasone (DRUG), AEZS-108 (DRUG), SCCC (DRUG).
Who is sponsoring clinical trial NCT01698281?
This trial is sponsored by AEterna Zentaris, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.